CTLA4 and neoplasm: In addition, dual inhibition of CTLA-4 and PD-1 recently has been shown to be more efficacious than a single therapy, mainly due to their distinctive mechanisms of action: the main sites of action for antibodies against CTLA-4 and PD-1 are thought to be within lymphoid tissues and tumor regions, respectively.